The Medtronic MiniMed™ 670G hybrid closed-loop system with SmartGuard™ technology was released for commercial use in the U.S. in March 2017. Data from patients previously managing their diabetes with multiple daily insulin injections (MDI) therapy who transitioned to the MiniMed™ 670G system are reported. MiniMed™ 670G system data from patients who voluntarily uploaded to CareLink™ Personal software, from 3/17/17 to 12/14/17 (n=158), were de-identified and analyzed if there were ≥7 days of sensor wear. Comparisons were made of glycemic metrics between 4,529 patient-days in the initial open-loop Manual Mode and 14,1patient-days after initiating closed-loop Auto Mode features. The Table shows glycemic metrics during Manual Mode and after Auto Mode start and that time spent in target range increased, while time spent in low and high glucose levels decreased. Real-world findings from patients previously using MDI who transitioned to the MiniMed™ 670G system demonstrated increased TIR and reduced time in hypoglycemia and hyperglycemia, consistent with pivotal trial1 results in patients previously using pump therapy +/- CGM. Prior MDI patients also showed greater TIR the more time spent in Auto Mode.


S. Gopalakrishnan: Employee; Self; Medtronic. P. Agrawal: None. M. Stone: None. C. Fogel: Employee; Self; Medtronic. S.W. Lee: Employee; Self; Medtronic.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at